Discovery of Novel Chemical Series of OXA-48 β-Lactamase Inhibitors by High-Throughput Screening
The major cause of bacterial resistance to β-lactams is the production of hydrolytic β-lactamase enzymes. Nowadays, the combination of β-lactam antibiotics with β-lactamase inhibitors (BLIs) is the main strategy for overcoming such issues. Nevertheless, particularly challenging β-lactamases, such as...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/7/612 |